Ubs Asset Management Americas Inc Amicus Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $379 Billion
  • Q1 2025

A detailed history of Ubs Asset Management Americas Inc transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,072,474 shares of FOLD stock, worth $6.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,072,474
Previous 958,671 11.87%
Holding current value
$6.51 Million
Previous $9.03 Million 3.09%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 19, 2025
BUY
$8.16 - $9.85 $928,632 - $1.12 Million
113,803 Added 11.87%
1,072,474 $8.75 Million
Q4 2024

Feb 14, 2025
BUY
$9.36 - $12.01 $4.42 Million - $5.67 Million
471,902 Added 96.95%
958,671 $9.03 Million
Q3 2024

Nov 14, 2024
SELL
$9.55 - $12.09 $451,810 - $571,977
-47,310 Reduced 8.86%
486,769 $5.2 Million
Q2 2024

Aug 13, 2024
BUY
$9.04 - $11.75 $2.56 Million - $3.32 Million
282,846 Added 112.58%
534,079 $5.3 Million
Q1 2024

May 15, 2024
SELL
$11.43 - $14.24 $75,060 - $93,514
-6,567 Reduced 2.55%
251,233 $2.96 Million
Q4 2023

Feb 14, 2024
BUY
$9.97 - $14.52 $117,257 - $170,769
11,761 Added 4.78%
257,800 $3.66 Million
Q3 2023

Nov 13, 2023
SELL
$11.78 - $13.86 $298,776 - $351,531
-25,363 Reduced 9.35%
246,039 $2.99 Million
Q1 2023

May 15, 2023
BUY
$10.91 - $13.54 $237,085 - $294,237
21,731 Added 8.7%
271,402 $3.01 Million
Q4 2022

Feb 14, 2023
BUY
$9.89 - $12.7 $284,604 - $365,467
28,777 Added 13.03%
249,671 $3.05 Million
Q3 2022

Nov 14, 2022
SELL
$9.82 - $12.75 $496,744 - $644,958
-50,585 Reduced 18.63%
220,894 $2.31 Million
Q2 2022

Aug 12, 2022
BUY
$6.23 - $11.12 $15,282 - $27,277
2,453 Added 0.91%
271,479 $2.92 Million
Q1 2022

May 16, 2022
SELL
$7.89 - $12.48 $82,537 - $130,553
-10,461 Reduced 3.74%
269,026 $2.55 Million
Q4 2021

Feb 14, 2022
SELL
$9.82 - $12.44 $60,432 - $76,555
-6,154 Reduced 2.15%
279,487 $3.23 Million
Q3 2021

Nov 15, 2021
SELL
$8.74 - $11.84 $342,573 - $464,080
-39,196 Reduced 12.07%
285,641 $2.73 Million
Q2 2021

Aug 16, 2021
BUY
$8.71 - $10.72 $89,608 - $110,287
10,288 Added 3.27%
324,837 $3.13 Million
Q1 2021

May 14, 2021
BUY
$9.2 - $23.86 $243,404 - $631,264
26,457 Added 9.18%
314,549 $3.11 Million
Q4 2020

Mar 01, 2021
SELL
$13.47 - $24.89 $16.4 Million - $30.3 Million
-1,217,486 Reduced 80.87%
288,092 $6.65 Million
Q3 2020

Nov 13, 2020
BUY
$12.89 - $15.89 $15.7 Million - $19.3 Million
1,215,044 Added 418.21%
1,505,578 $21.3 Million
Q2 2020

Aug 14, 2020
SELL
$8.86 - $15.69 $35,980 - $63,717
-4,061 Reduced 1.38%
290,534 $4.38 Million
Q1 2020

May 15, 2020
BUY
$6.63 - $11.16 $121,236 - $204,071
18,286 Added 6.62%
294,595 $2.72 Million
Q4 2019

Feb 14, 2020
BUY
$7.48 - $10.75 $210,846 - $303,021
28,188 Added 11.36%
276,309 $2.69 Million
Q3 2019

Nov 14, 2019
BUY
$8.02 - $13.25 $321,882 - $531,788
40,135 Added 19.3%
248,121 $1.99 Million
Q2 2019

Aug 15, 2019
BUY
$10.96 - $14.4 $550,389 - $723,139
50,218 Added 31.83%
207,986 $0
Q1 2019

May 14, 2019
BUY
$10.04 - $13.92 $205,277 - $284,608
20,446 Added 14.89%
157,768 $0
Q4 2018

Feb 13, 2019
BUY
$8.38 - $13.44 $166,016 - $266,259
19,811 Added 16.86%
137,322 $1.32 Million
Q3 2018

Nov 14, 2018
SELL
$11.6 - $16.54 $15,474 - $22,064
-1,334 Reduced 1.12%
117,511 $0
Q2 2018

Aug 14, 2018
SELL
$13.13 - $17.09 $67,186 - $87,449
-5,117 Reduced 4.13%
118,845 $0
Q1 2018

May 14, 2018
BUY
$13.76 - $17.12 $261,673 - $325,571
19,017 Added 18.12%
123,962 $0
Q4 2017

Feb 09, 2018
BUY
$12.51 - $16.24 $510,320 - $662,478
40,793 Added 63.59%
104,945 $0
Q3 2017

Nov 13, 2017
BUY
$11.74 - $15.78 $753,144 - $1.01 Million
64,152
64,152 $0

Others Institutions Holding FOLD

# of Institutions
315
Shares Held
319M
Call Options Held
378K
Put Options Held
575K
View Full List

About AMICUS THERAPEUTICS, INC.

FOLD Quotes by TradingView
  • Ticker FOLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 280,497,984
  • Market Cap $1.7B
  • Description
  • Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...
More about FOLD
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email